Coudereau, Rémy
Haem Rahimi, Muzhda
Lukaszewicz, Anne-Claire
Cour, Martin
Bidar, Frank
Argaud, Laurent
Venet, Fabienne
Monneret, Guillaume
Article History
Received: 14 December 2023
Accepted: 17 December 2023
First Online: 2 January 2024
Declarations
:
: Septic shock patients (Sepis-3 criteria) admitted to ICU of Hôpital E. Herriot (Hospices Civils de Lyon, Lyon, France) were included in the IMMUNOSEPSIS-4 cohort. This project was approved by Institutional Review Board for ethics (“Comité de Protection des Personnes Ouest II”: #2019-A00210-57). This study is registered at the French Ministry of Research and Teaching (#DC-2008–509), at the Commission Nationale de l’Informatique et des Libertés, and on clinicaltrials.gov (NCT02803346). COVID-19 ICU patients were enrolled in the RICO study. This project was approved by Institutional Review Board for ethics (“Comité de Protection des Personnes Ile de France 1”, n° RCB: 2020-A01079-30). This study is registered at the French Ministry of Research and Teaching (#DC-2008-509), at the Commission Nationale de l’Informatique et des Libertés, and on clinicaltrials.gov (NCT04392401). Peripheral blood from healthy volunteers (controls) was provided by the “Etablissement Français du Sang (EFS)” from Lyon. According to EFS standardized procedures for blood donation and to provisions of the article R.1243–49 and following ones of the French public health code, a written non-opposition to the use of donated blood for research purposes was obtained from controls.
: Not applicable.
: The authors declare that they have no competing interests.